Potential statin-drug interactions: Prevalence and clinical significance

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-8

  Zhelyazkova Savova, Maria ^a   Gancheva, Silvia ^a   Sirakova, Vera ^b  

^a MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

^b UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

Author keywords

Acenocoumarol statin interactions; CYP inhibitors; Hospital admission; Hospital discharge; INR; Statin drug interactions

Indexed keywords

EID: 84899501175     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-168     Document Type: Article

References (46)

1. Alsheikh-Ali AA, Karas RH (2005) Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 8(2):95-97
2. Andreasen AH, Brøsen K, Damkier P (2007) A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4. Epilepsia 48(3):490-496
3. Andrus MR (2004) Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 24(2):285-290
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S-198S. doi:10.1378/chest.08-0670
5. Bakhai A, Rigney U, Hollis S, Emmas C (2012) Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 21(5):485-493. doi:10.1002/pds.2308
6. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C (2007) Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 81(5):679-684
7. Beinema M, Brouwers JRBJ, Schalekamp T, Wilffert B (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100:1052-1057. doi:10.1160/TH08-04-0116
8. Bellosta S, Corsini A (2012) Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 11(6):933-946. doi:10.1517/14740338.2012.712959
9. Bottorff MB (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97((8) Suppl 1):S27-S31
10. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH (2000) Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 21(9):353-364
11. Delavenne X, Laporte S, Demasles S, Mallouk N, Basset T, Tod M, Girard P, Mismetti P (2009) Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. Fundam Clin Pharmacol 23(1):127-135. doi:10.1111
12. Drugs.com. Drug Interactions Checker. http://www.drugs.com/drug_interactions.html
13. Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24(5):429-440
14. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J (2002) An examination of the effect of Cytochrome P450 drug interactions of Hydroxymethylglutaryl- Coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study. Clinical Therapeutics 24(12):2126-2136
15. FDA Drug Safety Communication (2011) New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. U.S. Food and Drug Administration 10903, New Hampshire Avenue Silver Spring, MD 20993
16. Gladding P, Pilmore H (2004) Potentially fatal interaction between diltiazem and statins. Ann Int Med 140(8):676
17. Grau E, Perella M, Pastor E (1996) Simvastatin-oral anticoagulant interaction. Lancet 347(8998):405-406
18. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V (2006) The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 62(4):291-296
19. Horn JR, Hansten PD (2011) Drug interactions with simvastatin: the risk continues. Pharmacy Times 10:48
20. Hu M, Mak VW, Tomlinson B (2011) Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. J Clin Pharm Ther 36(3):419-425. doi:10.1111/j.1365-2710.2010.01184.x
21. Jankel CA, Fitterman LK (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9(1):51-59
22. Kanathur N, Mathai MG, Byrd RP, Jr, Fields CL, Roy TM (2001) Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 94(9):339-341
23. Kantola T, Kivistö KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64(2):177-182
24. Lee AJ, Maddix DS (2001) Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 35(1):26-31
25. Lewin JJ, Nappi JM, Taylor MH (2002) Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 36(10):1546-1549
26. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N (2011) Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 66(2):134-136
27. McKenney JM (2005) Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 62(10):1033-1047
28. Medscape. Drug Interaction Checker. http://www.medscape.com/druginfo/druginterchecker
29. MERCK SHARP & DOHME LTD (2008) Highlights of prescribing information for ZOCOR (simvastatin), Cramlington, Northumberland, UK NE23 3JU
30. Molden E, Andersson KS (2007) Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy 27(4):603-607
31. Mondillo S, Ballo P, Galderisi M (2005) Rosuvastatin-Acenocoumarol Interaction. Clin Ther 27(6):782-784. doi:10.1016/j.clinchera.06.007
32. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35(9):1096-1107
33. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S (2005) Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28(3):263-275
34. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG (2004) Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 38(6):978-981
35. Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K (2006) Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 23(3):506-512
36. Schalekamp T, van Geest-Daalderop JH, Kramer MH, van Holten-Verzantvoort AT, de Boer A (2007) Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol 63(4):335-343
37. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S (2010) Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 123(2):151-157
38. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112(1):71-105
39. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW (2005) Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 45:927-934
40. Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S (2007) The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 14(1):30-40
41. Tirkkonen T, Ryynänen A, Vahlberg T, Irjala K, Klaukka T, Huupponen R, Laine K (2008) Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Drug Saf 31(3):231-240
42. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjörndal T (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59(12):879-882
43. van Schie RM, Verhoef TI, Boejharat SB, Schalekamp T, Wessels JA, le Cessie S, Rosendaal FR, van der Meer FJ, de Boer A, der Zee AH M-v (2012) Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact 27(4):229-234
44. Westergren T, Johansson P, Molden E (2007) Probable warfarin-simvastatin interaction. Ann Pharmacother 41(7):1292-1295
45. Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41(5):343-370
46. Yu CY, Campbell SE, Zhu B, Knadler MP, Small DS, Sponseller CA, Hunt TL, Morgan RE (2012) Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin 28(2):187-194